Effects of phosphodiesterase 7 inhibition by RNA interference on the gene expression and differentiation of human mesenchymal stem cell-derived osteoblasts

Bone

Volumn 43, Issue 1, 2008, Pages 84-91

  Pekkinen, Minna ^a   Ahlström, Mikael E B ^a   Riehle, Ulrike ^b   Huttunen, Minna M ^a   Lamberg Allardt, Christel J E ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HOHENHEIM   (Germany)

Author keywords

cAMP phosphodiesterase; Gene expression; Mineralization; Osteoblast; RNAi

Indexed keywords

ALIZARIN RED S; BETA CATENIN; CALCITRIOL; CAMP RESPONSIVE ELEMENT BINIDING PROTEIN 5; CASPASE 8; COMPLEMENTARY DNA; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; FORSKOLIN; OSTEOCALCIN; PHOSPHODIESTERASE; PHOSPHODIESTERASE 8 INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE VII; PROCOLLAGEN C PROTEINASE; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; BONE DEVELOPMENT; BONE MARROW; BONE METABOLISM; CELL CULTURE; CELL DIFFERENTIATION; DNA MICROARRAY; GENE EXPRESSION; GENE SEQUENCE; GENE SILENCING; GENETIC VARIABILITY; HORMONAL REGULATION; HUMAN; HUMAN TISSUE; MESENCHYMAL STEM CELL; MINERALIZATION; OSTEOBLAST; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR GENE; RNA INTERFERENCE; RNA ISOLATION; UPREGULATION;

BASE SEQUENCE; CALCIFICATION, PHYSIOLOGIC; CELL DIFFERENTIATION; CELLS, CULTURED; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 7; DNA PRIMERS; GENE EXPRESSION; GENE SILENCING; HUMANS; MESENCHYMAL STEM CELLS; OSTEOBLASTS; PHOSPHODIESTERASE INHIBITORS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 44949224387     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2008.02.021     Document Type: Article

References (73)

1. Hannon G.J. RNA interference. Nature 418 (2002) 244-251
2. Elbashir S.M., Harborth J., Weber K., and Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods (Duluth) 26 (2002) 199-213
3. Uprichard S.L. The therapeutic potential of RNA interference. FEBS Lett 579 (2005) 5996-6007
4. Beavo J.A. Cyclic nucleotide phoshodiesterases: functional implications of multiple isoforms. Physiol Rev 75 (1995) 725-748
5. Soderling S.H., and Beavo J.A. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 12 (2000) 174-179
6. Mishaela R., Rubin M.D., and Bilezikian J.P. New anabolic therapies in osteoporosis. Curr Opin Rheumatol 14 (2002) 433-440
7. Hodsman A.B., Bauer D.C., Dempster D.W., Dian L., Hanley D.A., Harris S.T., et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26 (2005) 688-703
8. Koh A.J., Beecher C.A., Rosol T.J., and McCauley L.K. 3′,5′-Cyclic adenosine monophosphate activation in osteoblastic cells: effects on parathyroid hormone-1 receptors and osteoblastic differentiation in vitro. Endocrinology 140 (1999) 3154-3162
9. Kulkarni N.H., Halladay D.L., Miles R.R., Gilbert L.M., Frolik C.A., Galvin R.J., et al. Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem 95 (2005) 1178-1190
10. Houslay M.D., and Adams D.R. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370 (2003) 1-18
11. Conti M., Richter W., Mehats C., Livera G., Park J.Y., and Jin C. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278 (2003) 5493-5496
12. Manganiello V.C., Murata T., Taira M., Belfrage P., and Degerman E. Diversity in cyclic nucleotide phoshodiesterase isozyme families. Arch Biochem Biophys 322 (1995) 1-13
13. Mehats C., Andersen C.B., Filopanti M., Jin S.L., and Conti M. Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends Endocrin Metab 13 (2002) 29-35
14. Soderling S.H., Bayuga S.J., and Beavo J.A. Cloning and characterization of a cAMP-specific cyclic nucleotide phoshodiesterase. Proc Natl Acad Sci U S A 95 (1998) 8991-8996
15. Soderling S.H., Bayuga S.J., and Beavo J.A. Identification and characterization of a novel family of cyclic nucleotide phoshodiesterases. J Biol Chem 273 (1998) 15553-15558
16. Fawcett L., Baxendale R., Stacey P., McGrouther C., Harrow I., Soderling S., et al. Molecular cloning and characterization of a distinct human phoshodiesterase gene family: PDE 11A. Proc Natl Acad Sci U S A 97 (2000) 3702-3707
17. Miyamoto K., Waki Y., Horita T., Kasugai S., and Ohya K. Reduction of bone loss by denbufylline, an inhibitor of phosphodiesterase 4. Biochem Pharmacol 54 (1997) 613-617
18. Miyamoto K., Suzuki H., Yamamoto S., Saitoh Y., Ochiai E., Moritani S., et al. Prostaglandin E2-mediated anabolic effect of a novel inhibitor of phosphodiesterase 4, XT-611, in the in vitro bone marrow culture. J Bone Miner Res 18 (2003) 1471-1477
19. Kinoshita T., Kobayashi S., Ebara S., Yoshimura Y., Horiuchi H., Tsutsumimoto T., et al. Phosphodiesterase inhibitors, pentoxifylline and rolipram, increase bone mass mainly by promoting bone formation in normal mice. Bone 27 (2000) 811-817
20. Wakabayashi S., Tsutsumimoto T., Kawasaki S., Kinoshita T., Horiuchi H., and Takaoka K. Involvement of phosphodiesterase isozymes in osteoblastic differentiation. J Bone Mineral Res 17 (2002) 249-256
21. Scutt A., Beier N., and Fittschen C. EMD273316 & EMD95833, type 4 phosphodiesterase inhibitors, stimulate fibroblastic-colony formation by bone marrow cells via direct inhibition of PDE4 and the induction of endogenous prostaglandin synthesis. BMC Pharmacol 4 (2004) 10
22. Rawadi G., Ferrer C., Spinella-Jaegle S., Roman-Roman S., Bouali Y., and Baron R. 1-(5-oxohexyl)-3,7-Dimethylxanthine, a phosphodiesterase inhibitor, activates MAPK cascades and promotes osteoblast differentiation by a mechanism independent of PKA activation (pentoxifylline promotes osteoblast differentiation). Endocrinology 142 (2001) 4673-4682
23. Ahlstrom M., and Lamberg-Allardt C. Rapid protein kinase A-mediated activation of cyclic AMP-phosphodiesterase by parathyroid hormone in UMR-106 osteoblast-like cells. J Bone Miner Res 12 (1997) 172-178
24. Ahlstrom M., and Lamberg-Allardt C. Regulation of adenosine 3′,5′-cyclic monophosphate (cAMP) accumulation in UMR-106 osteoblast-like cells: role of cAMP-phosphodiesterase and cAMP efflux. Biochem Pharmacol 58 (1999) 1335-1340
25. Ahlstrom M., and Lamberg-Allardt C. Inactivation of atrial natriuretic factor-stimulated cyclic guanosine 3′,5′-monophosphate (cGMP) in UMR-106 osteoblast-like cells. Biochem Pharmacol 59 (2000) 1133-1139
26. Ahlstrom M., Pekkinen M., Huttunen M., and Lamberg-Allardt C. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation. Cell Mol Biol Lett 10 (2005) 305-319
27. Ahlstrom M., Pekkinen M., Huttunen M., and Lamberg-Allardt C. Dexamethasone down-regulates cAMP-phosphodiesterase in human osteosarcoma cells. Biochem Pharmacol 69 2 (2005) 267-275
28. Sasaki T., Kotera J., Yuasa K., and Omori K. Identification of human PDE7B, a cAMP-specific phosphodiesterase. Biochem Biophys Res Commun 271 (2000) 575-583
29. Gardner C., Robas N., Cawkill D., and Fidock M. Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase. Biochem Biophys Res Commun 272 (2000) 186-192
30. Smith S.J., Brookes-Fazakerley S., Donnelly L.E., Barnes P.J., Barnette M.S., and Giembycz M.A. Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. Am J Physiol Lung Cell Mol Physiol 284 (2003) L279-L289
31. Giembycz M.A., Corrigan C.J., Seybold J., Newton R., and Barnes P.J. Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol 118 (1996) 1945-1958
32. Li L., Yee C., and Beavo J.A. CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science 283 (1999) 848-851
33. Kobayashi T., Gamanuma M., Sasaki T., Yamashita Y., Yuasa K., Kotera J., and Omori K. Molecular comparison of rat cyclic nucleotide phosphodiesterase 8 family: unique expression of PDE8B in rat brain. Gene 319 (2003) 21-31
34. Kerr M.K., and Churchill G.A. Experimental design for gene expression microarrays. Biostatistics 2 (2001) 183-201
35. Fisher D.A., Smith J.F., Pillar J.S., St Denis S.H., and Cheng J.B. Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. Biochem Biophys Res Commun 246 (1998) 570-577
36. Omori K., and Kotera J. Overview of PDEs and their regulation. Circ Res 100 (2007) 309-327
37. Huttunen M.M., Pekkinen M., Ahlstrom M.E., and Lamberg-Allardt C.J. Effects of bioactive peptides isoleucine-proline-proline (IPP), valine-proline-proline (VPP) and leucine-lysine-proline (LKP) on gene expression of osteoblasts differentiated from human mesenchymal stem cells. Br J Nutr 98 (2007) 780-788
38. Stanford C.M., Jacobson P.A., Eanes E.D., Lembke L.A., and Midura R.J. Rapidly Forming Apatitic mineral in an osteoblastic cell line (UMR 106-01 BSP). J Biol Chem 270 (1995) 9420-9428
39. Smith S.J., Cieslinski L.B., Newton R., Donnelly L.E., Fenwick P.S., Nicholson A.G., et al. Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. Mol Pharmacol 66 6 (2004) 1679-1689
40. Jackson E.K., Ren J., Zacharia L.C., and Mi Z. Characterization of renal ecto-phosphodiesterase. J Pharmacol Exp Ther 321 2 (2007) 810-815
41. Bantounas I., Phylactou L.A., and Uney J.B. RNA interference and the use of small interfering RNA to study gene function in mammalian systems. J Mol Endocrinol 33 (2004) 545-557
42. Semizarov D., Kroeger P., and Fesik S. siRNA-mediated gene silencing: a global genome view. Nucleic Acids Res 32 (2004) 3836-3845
43. Mousses S., Caplen N.J., Cornelison R., Weaver D., Basik M., Hautaniemi S., et al. RNAi microarray analysis in cultured mammalian cells. Genome Res 13 (2003) 2341-2347
44. Price P.A., Otsuka A.A., Poser J.W., Kristaponis J., and Raman N. Characterization of a gamma-carboxyglutamic acid-containing protein from bone. Proc Natl Acad Sci U S A 73 (1976) 1447-1451
45. Lajeunesse D., Kiebzak G.M., Frondoza C., and Sacktor B. Regulation of osteocalcin secretion by human primary bone cells and by the human osteosarcoma cell line MG-63. Bone Miner 14 (1991) 237-250
46. Noda M., Yoon K., and Rodan G.A. Cyclic AMP-mediated stabilization of osteocalcin mRNA in rat osteoblast-like cells treated with parathyroid hormone. J Biol Chem 263 (1988) 18574-18577
47. Theofan G., and Price P.A. Bone Gla protein messenger ribonucleic acid is regulated by both 1,25-dihydroxyvitamin D3 and 3′,5′-cyclic adenosine monophosphate in rat osteosarcoma cells. Mol Endocrinol 3 (1989) 36-43
48. Drissi H., Hott M., Marie P.J., and Lasmoles F. Expression of the CT/CGRP gene and its regulation by dibutyryl cyclic adenosine monophosphate in human osteoblastic cells. J Bone Miner Res 12 (1997) 1805-1814
49. Boguslawski G., Hale Laura V., Yu X.P., Miles R.R., Onyia J.E., Santerre R.F., et al. Activation of osteocalcin transcription involves interaction of protein kinase A- and protein kinase C-dependent pathways. J Biol Chem 275 (2000) 999-1006
50. Canalis E., Economides A.N., and Gazzerro E. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 24 (2003) 218-235
51. Uzel M.I., Scott I.C., Babakhanlou-Chase H., Palamakumbura A.H., Pappano W.N., Hong H.H., Greenspan D.S., and Trackman P.C. Multiple bone morphogenetic protein 1-related mammalian metalloproteinases process pro-lysyl oxidase at the correct physiological site and control lysyl oxidase activation in mouse embryo fibroblast cultures. J Biol Chem 276 (2001) 22537-22543
52. Wozney J.M. Overview of bone morphogenetic proteins. Spine 27 (2002) 52-58
53. Nakashima A., Katagiri T., and Tamura M. Cross-talk between Wnt and bone morphogenetic protein 2 (BMP-2) signaling in differentiation pathway of C2C12 myoblasts. J Biol Chem 280 (2004) 37660-37668
54. Nelson W.J., and Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303 (2004) 1483-1487
55. Rawadi G., and Roman-Roman S. Wnt signalling pathway: a new target for the treatment of osteoporosis. Expert Opin Ther Targets 9 (2005) 1063-1077
56. Canalis E., Deregowski V., Pereira R.C., and Gazzerro E. Signals that determine the fate of osteoblastic cells. J Endocrinol Invest 28 (2005) 3-7
57. Mogi M., and Togari A. Activation of caspases is required for osteoblastic differentiation. J Biol Chem 278 (2003) 47477-47482
58. Tanaka H., and Seino Y. Direct action of 1,25-dihydroxyvitamin D on bone: VDRKO bone shows excessive bone formation in normal mineral condition. J Steroid Biochem 89-90 (2004) 343-345
59. Sooy K., Sabbagh Y., and Demay M.B. Osteoblasts lacking the vitamin D receptor display enhanced osteogenic potential in vitro. J Cell Biochem 94 (2005) 81-87
60. Sakamoto M.K., Suzuki K., Takiya S., Yoshimura Y., Imai T., Matsumoto A., et al. Developmental profiles of phosphorylated and unphosphorylated CREBs in murine calvarial MC3T3-E1 cells. J Biochem 3 (1998) 399-407
61. Nakata A., Ogawa K., Sasaki T., Koyama N., Wada K., Kotera J., et al. Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol 128 (2002) 460-466
62. Baillie G.S., Scott J.D., and Houslay M.D. Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract. FEBS Lett 579 (2005) 3264-3270
63. Prestwich S.A., Forda S.R., and Dolphin A.C. Adenosine antagonists increase spontaneous and evoked transmitter release from neuronal cells in culture. Brain Res 405 (1987) 130-139
64. Schiffman S.S., Gill J.M., and Diaz C. Methyl xanthines enhance taste: evidence for modulation of taste by adenosine receptor. Pharmacol Biochem Behav 22 (1985) 195-203
65. Giembycz M.A., Corrigan C.J., Seybold J., Newton R., and Barnes P.J. Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol 118 (1996) 1945-1958
66. Bartsch O., Bartlick B., and Ivell R. Phosphodiesterase 4 inhibition synergizes with relaxin signaling to promote decidualization of human endometrial stromal cells. J Clin Endocrinol Metab 89 (2004) 324-334
67. Leroy M.J., Mehats C., Duc-Goiran P., Tanguy G., Robert B., Dallot E., et al. Effect of pregnancy on PDE4 cAMP-specific phosphodiesterase messenger ribonucleic acid expression in human myometrium. Cell Signal 11 (1999) 31-37
68. Wordinger R.J., Agarwal R., Talati M., Fuller J., Lambert W., and Clark A.F. Expression of bone morphogenetic proteins (BMP), BMP receptors, and BMP associated proteins in human trabecular meshwork and optic nerve head cells and tissues. Mol Vis 8 (2002) 241-250
69. Kuliwaba J.S., Findlay D.M., Atkins G.J., Forwood M.R., and Fazzalari N.L. Enhanced expression of osteocalcin mRNA in human osteoarthritic trabecular bone of the proximal femur is associated with decreased expression of interleukin-6 and interleukin-11 mRNA. J Bone Miner Res 15 (2000) 332-341
70. Gomes A.C., Jonsson G., Mjornheim S., Olsson T., Hillert J., and Grandien A. Upregulation of the apoptosis regulators cFLIP, CD95 and CD95 ligand in peripheral blood mononuclear cells in relapsing-remitting multiple sclerosis. J Neuroimmunol 135 (2003) 126-134
71. Wang J., Krill D., Torbenson M., Wang Q., Bisceglia M., Stoner J., et al. Expression of cadherins and catenins in paired tumor and non-neoplastic primary prostate cultures and corresponding prostatectomy specimens. Urol Res 28 (2000) 308-315
72. Veitch D.P., Nokelainen P., McGowan K.A., Nguyen T.T., Nguyen N.E., Stephenson R., et al. Mammalian tolloid metalloproteinase, and not matrix metalloprotease 2 or membrane type 1 metalloprotease, processes laminin-5 in keratinocytes and skin. J Biol Chem 278 (2003) 15661-15668
73. Hamajima S., Hiratsuka K., Kiyama-Kishikawa M., Tagawa T., Kawahara M., Ohta M., et al. Effect of low-level laser irradiation on osteoglycin gene expression in osteoblasts. Laser Med Sci 18 (2003) 78-82